Counterparts Clause Example from Business Contracts
This example Counterparts clause appears in 27 contracts from 25 companies
CHATHAM LODGING TRUST UP TO $50,000,000 OF SHARES SALES AGREEMENT (Filed With SEC on January 13, 2015)
CHATHAM LODGING TRUST UP TO $50,000,000 OF SHARES CONTROLLED EQUITY OFFERINGSM SALES AGREEMENT (Filed With SEC on January 31, 2014)
CELATOR PHARMACEUTICALS, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on October 16, 2015)
Cyclacel Pharmaceuticals,Inc. Up to $8,350,000 of Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on July 13, 2015)
Equity Distribution Agreement (Filed With SEC on July 15, 2015)
IMPAC MORTGAGE HOLDINGS, INC. Up to $25,000,000 of Shares of Common Stock (par value $0.01 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on December 3, 2015)
INTRA-CELLULAR THERAPIES, INC. AT-THE-MARKET OFFERING PROGRAM $50,000,000 SALESAGREEMENT (Filed With SEC on May 28, 2015)
ROKA BIOSCIENCE, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on October 30, 2015)
KARYOPHARM THERAPEUTICS INC. Shares of Common Stock (par value$0.0001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on December 8, 2015)
SYNTA PHARMACEUTICALS CORP. $100,000,000 SALES AGREEMENT (Filed With SEC on October 16, 2015)
CytoSorbentsCorporation Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on November 5, 2015)
THRESHOLD PHARMACEUTICALS, INC. $50,000,000 SALES AGREEMENT (Filed With SEC on November 2, 2015)
GLADSTONE LAND CORPORATION UP TO $30,000,000 OF SHARES OF COMMON STOCK CONTROLLED EQUITY OFFERINGSM SALES AGREEMENT (Filed With SEC on August 7, 2015)
GLADSTONE LAND CORPORATION UP TO $30,000,000 OF SHARES OF COMMON STOCK CONTROLLED EQUITY OFFERINGSM SALES AGREEMENT (Filed With SEC on August 7, 2015)
MATINAS BIOPHARMA HOLDINGS, INC. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on April 28, 2017)
GLOBAL MEDICAL REIT INC. UP TO $50,000,000 SHARES OF COMMON STOCK CONTROLLED EQUITY OFFERINGSM SALES AGREEMENT (Filed With SEC on August 25, 2017)
KALVISTA PHARMACEUTICALS, INC. COMMON STOCK (par value$0.001 per share) AT-THE-MARKET SALES AGREEMENT (Filed With SEC on July 13, 2017)
Sales Agreement, dated as of October 13, 2017, by and between the Company and Cowen and Company, LLC (Filed With SEC on October 13, 2017)
Controlled Equity OfferingSM Sales Agreement, dated as of June 27, 2017, by and between Chembio Diagnostics, Inc. and Cantor Fitzgerald & Co (Filed With SEC on June 27, 2017)
NOVUS THERAPEUTICS, INC. Shares of Common Stock (par value $0.001 per share) Equity Distribution Agreement (Filed With SEC on August 22, 2017)
INTREPID POTASH, INC. Up to $40,000,000 Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on May 26, 2017)
Spring Bank Pharmaceuticals, Inc. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on August 18, 2017)
Sales Agreement dated October 13, 2017 by and between Albireo Pharma, Inc. and Cowen and Company, LLC (Filed With SEC on October 13, 2017)
Sales Agreement dated September 15, 2017 by and between uniQure N.V. and Leerink Partners LLC (Filed With SEC on September 18, 2017)
TIER REIT, INC. UP TO $125,000,000 SHARES OF COMMON STOCK CONTROLLED EQUITY OFFERING SALES AGREEMENT (Filed With SEC on May 10, 2017)
